IFNG and neoplasm: Preliminary analyses showed dose-limiting toxicity (due to cytokine release syndrome) in one of thirty patients receiving 8mg mRNA-2752, increased cytokine IFNγ and TNFα expression in both tumor and plasma, and partial responses in two of the forty-five patients, highlighting some potential (as well as limitations) of this approach (44).